Patient recruitment and retention in this area is notoriously difficult. Julius Clinical has the leading scientific experts, experienced local investigators, and fine-tuned screening procedures to minimize this obstacle and provide the patient enrolment and retention your trial requires.
Prof. Dr. Diederick E. (Rick) Grobbee is Chief Scientific Officer at Julius Clinical and a professor of clinical epidemiology at the University Medical Centre (UMC) Utrecht, the Netherlands. His other current roles include chair of the circulatory health area at UMC Utrecht.
We collaborate with Prof. dr. Christophe Moreno, M.D., who is an expert in gastroenterology and hepatology and clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium. He is a valuable consultant to our MASH Clinical team.
Prof. Dr. Hiddo Lambers Heerspink is our Associated Scientific Leader for kidney disease clinical trials. Prof. Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of kidney and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He has successfully led and currently leads numerous clinical trials with new interventions to reduce diabetes related kidney and cardiovascular complications.
Prof. Dr. Manuel Castro Cabezas works as Chief Scientific Officer at Julius Clinical. He is also a senior consultant for endocrinology, internal medicine, and vascular diseases at the Franciscus Gasthuis Rotterdam and associate professor of medicine at Erasmus Medical Center, Rotterdam, the Netherlands. Prof. Castro Cabezas has participated in international clinical trials in the fields of lipid management, diabetes and obesity and published over 200 papers in peer reviewed journals dealing with postprandial lipemia, diabetes, insulin resistance, obesity, metabolic syndrome, familial combined hyperlipidemia, HIV lipodystrophy and free fatty acid metabolism.
Our Scientific Networks
Some highlighted studies
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
On NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...
Explore our cardio-metabolic capabilities, studies, and other resources.
"*" indicates required fields
"*" indicates required fields
